Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda

By Reuters
| April 25, 2024

The New Jersey-based drugmaker said it expected annual earnings of $8.53 to $8.65 per share, up from its previous forecast of $8.44 to $8.59. Analysts had estimated earnings of $8.56 per share.

Full story

#1

Recent research on Paxlovid shows there is "solid data on its effectiveness," a co-author of the study told HealthLeaders. ...

A new personal protective equipment manufacturing company is set to open in Cincinnati next year. ...